IMMX - NASDAQ

Immix Biopharma, Inc.

Immix Biopharma, Inc.

IMMXยทNASDAQ

$8.44

+0.90%
HealthcareBiotechnology

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$459.23M
EPS-0.8900
P/E Ratio-9.48
Earnings Date08/14/2026
Immix Biopharma, Inc.

Immix Biopharma, Inc. Fair Value Envelope

IMMX ยท NASDAQ

Our analysis suggests that IMMX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $8.44, this represents a potential HIDDEN relative to our calculated worth for Immix Biopharma, Inc..

HIDDEN
Intrinsic Value
Current Price: $8.44

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$20.7M
+ Cash & Equivalents$93.9M
Firm Value$73.2M
- Debt$1.1M
Equity Value$72.1M
/ Shares Outstanding28,806,794B
DCF Value$3
OVERVALUED BY 70%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$12.0M
-$6.0M
-$3.0M
-$1.5M
-$747.8K
-$373.9K
-$187.0K
-$93.5K
-$46.7K
-$23.4K
Maintenance CapEx
-$73.3K
-$36.6K
-$18.3K
-$9.2K
-$4.6K
-$2.3K
-$1.1K
-$573
-$286
-$143
Owner Earnings
-$12.0M
-$6.0M
-$3.0M
-$1.5M
-$752.4K
-$376.2K
-$188.1K
-$94.1K
-$47.0K
-$23.5K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$11.1M
-$5.2M
-$2.4M
-$1.1M
-$512.1K
-$237.1K
-$109.8K
-$50.8K
-$23.5K
-$10.9K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your IMMX research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.